Drug intelligence / Profile preview

CJ-006

Development stage: Preclinical
Lead developer: Guangdong Xijie Pharmaceutical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems

Overview

CJ-006 is a small molecule therapeutic utilizing a nanocrystal formulation, currently in preclinical development by Guangdong Xijie Pharmaceutical. It is categorized as a Class 2 improved new drug under Chinese regulatory standards, indicating it is a modified version of a previously approved drug, likely optimized for improved solubility or bioavailability. The primary indications for CJ-006 are drug-resistant prostate cancer and diabetic nephropathy.

Beyond the preview

Go deeper on CJ-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-006.

Explore the full profile